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1. Introduction  
Anaphylaxis is an acute systemic allergic reaction that can potentially be life-threatening. 
Therefore it has to be diagnosed and treated promptly. It can occur after exposure to various 
triggers or spontaneously and can potentially affect multiple organ systems and prompt and 
definite treatment may be life saving. In this chapter, possible triggers of anaphylaxis, 
clinical manifestations, diagnosis and management will be discussed. 
2. Epidemiology  
Anaphylaxis is defined as a “severe, potentially fatal, systemic allergic reaction that occurs 
suddenly after contact with an allergy-causing substance” (Sampson et al., 2006). As there is 
no unified method of obtaining data about anaphylaxis, its incidence is very difficult to 
evaluate clearly. A substantial portion of the existing data on the epidemiology of 
anaphylaxis has come from investigations that have limited scope population sources, such 
as surveys and volunteer registries (Harduar-Morano et al., 2011). Lifetime prevalence is 
estimated as 0.05% to 2% (Simons, 2008). Recent studies confirm that the incidence of 
anaphylaxis, particularly food-induced anaphylaxis, is increasing world-wide (Chiu & 
Kelly, 2005). A very recent study investigated a large diverse population with anaphylaxis 
diagnosed in emergency departments using rigorous descriptive and analytic evaluation of 
risk factors, such as sex, race, ethnicity, and age (Harduar-Morano et al., 2011). In this study 
the highest observed rates were among the youngest male subjects (8.2/100,000 aged  
0-4 years) and among adult female subjects (15-54 years) grouped in 10-year age categories 
(9,9-10.9/100,000). Previous epidemiologic studies also suggested that until age 15 years, 
there is a predilection for males, but after age 15 years, there is a predilection for females. 
Different trigger factors predominate in different age groups; for example, fatalities from 
food-induced anaphylaxis peak in adolescents and young adults, and fatalities from 
anaphylaxis triggered by insect stings, diagnostic agents, and medications predominate in 
middle-aged and older adults (Simons, 2008). Atopy is an associated risk factor for 
anaphylaxis triggered by food, exercise, and latex but not for anaphylaxis triggered by insect 
stings, ǃ-lactam antibiotics (Chiu and Kelly, 2005). In addition, asthma was reported in 23% 
of 142 patients with anaphylaxis who presented to an emergency department from 1998 to 
1999 (Brown et al., 2001). 
www.intechopen.com
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
168 
3. Pathogenesis  
The underlying pathogenesis of human anaphylaxis commonly involves an immunologic 
mechanism in which IgE is synthesized in response to allergen exposure and becomes fixed 
to high affinity receptors for IgE (FcεRI receptors) on the surface membranes of mast cells 
and basophils (Simons, 2010). Other potential immunologic mechanisms in anaphylaxis 
include involvement of immune aggregates, IgG, IgM, platelets, and T cells; shift in 
eicosanoid metabolism toward leukotriene formation; and activation of the complement or 
coagulation systems (Simons, 2008).  
The mast cells and basophils are central players in allergic reaction (Rivera & Gilfillan, 2006). 
Activation of these cells induces the release of preformed inflammatory mediators localized 
in specialized granules and the de novo synthesis and secretion of cytokines, chemokines, 
and eicosanoids. Appropriate activation of mast cells is mediated by a number of factors, 
including the cells’ ability to distinguish activating or inhibiting stimuli and the strength 
and duration of stimulus. FcεRI on mast cells is comprised of an IgE- binding ǂ chain, a 4-
transmembrane spanning ǃ chain and a monodimer of Ǆ chains. The ǃ chain functions as an 
amplifying modul for this receptor. The Ǆ chain monodimer imports signaling competence 
to this receptor. It has been demonstrated that both the ǃ and Ǆ chains function to generate 
positive signals that are key in initiating and amplifying the mast cells’ effector responses. 
However, recent evidence suggests that these two chains can also function to negatively 
regulate cell activation and effector responses (Rivera & Gilfillan, 2006).  
Current knowledge suggests that mast cell’s response to a stimulus is very complex. A 
number of molecules play role in the coordination and control of degranulation. FcεRI- 
mediated activation of mast cells requires both Lyn and the related Src PTK Fyn as receptor-
proximal kinases. Fyn-deficient and Lyn/Fyn double deficient mice showed defective 
passive systemic anaphylaxis responses indicating a positive role for Fyn in promoting mast 
cell degranulation in vivo (Rivera & Gilfillan, 2006). 
Recent investigations showed that stem cell factor and its receptor Kit are fundamentally 
important in IgE/antigen-induced mast cell activation, and concurrent inhibition of Kit- and 
FcεRI-mediated signaling achieves coordinated suppression of human mast cell activation 
(Jensen et al., 2007). Inhibitory sialic acid-binding immunoglobulin-like lectins are expressed 
on human mast cells, on which Siglec-8 engagement results in inhibition of FcεRI-dependent 
mediator release without apoptosis (Yokoi et al., 2006). Sphingosine kinases are reported to 
be determinants of mast cell responsiveness (Olivera et al., 2007).  
In some individuals described as having idiopathic anaphylaxis, FcεRI receptors may be 
aggregated through autoimmune mechanisms (Simons, 2010). Nonimmunological factors, 
which activate mast cells by mechanisms not yet fully understood, include exercise, cold air 
or water exposure, radiation, ethanol, insect venom, constituents, radiocontrast media and 
medications such as opioids and vancomycin (Simons, 2010). Regardless of the immunologic 
or nonimmunologic triggering mechanism, and regardless of whether FcεRI or other 
receptors such as G protein-coupled receptors or Toll-like receptors are activated, mast cells 
and basophils play an important role in initiating and amplifying the acute allergic 
response. They release mediators of inflammation including histamine, proteases such as 
tryptase, mast cell carboxypeptidase A3 and chymase, lipids such as platelet activating 
factor (PAF), prostaglandines (PGD2) and leukotrienes (LTC4) as well as chemokines and 
cytokines (Simons, 2008). 
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3.1 Animal models 
Studies with murine models demonstrate 2 pathways of systemic anaphylaxis: one 
mediated by IgE, FcεRI, mast cells, histamine, and platelet-activating factor (PAF), and the 
other mediated by IgG, FcγRIII, macrophages, and PAF. The former pathway requires much 
less antibody and antigen than the latter. As a result, IgG antibody can block IgE-mediated 
anaphylaxis induced by small quantities of antigen without mediating FcγRIII-dependent 
anaphylaxis (Finkelman et al., 2005).  
The IgE pathway is most likely responsible for most human anaphylaxis, which generally 
involves small amounts of antibody and antigen; similarities in the murine and human 
immune systems suggest that the IgG pathway might mediate disease in persons repeatedly 
exposed to large quantities of antigen. Antigen cross-linking of antigen specific IgE bound to 
mast cell FcεRI stimulates mast cell degranulation, with the rapid release of histamine and 
serotonin and the synthesis and secretion of platelet activation factor (PAF) and leukotrienes. 
These mediators act on target cells to increase vascular permeability which cause depletion of 
intravascular volume. The resulting decrease in vital organ perfusion is the primary cause of 
the symptoms that characterize murine anaphylaxis (Finkelman et al., 2005). 
The other pathway in mouse is Ig-E independent pathway. As contrary of clasical pathway, at 
first immunized and antigen challenged mice had anaphylaxis despite the absence of mast 
cells, FcεRI and IgE. This pathway is also complement independent but requires IgG antibody, 
macrophages, FcǄRIII and PAF. Regardless which pathway takes place, mouse anaphylaxis 
occurs in very short time and displays similar symptoms. Potentially important differences 
between mouse and human anaphylaxis are proposed as follows: 1. Mouse IgG has some 
ability to activate mast cells, an effect that is not shared by any human IgG isotype, 2. IgE binds 
weakly to murine, but not human low-affinity FcǄRs, 3. Human but not mouse macrophages, 
Langerhans cells and dendritic cells can express FcεRI, and 4. Human platelets, B cells and 
natural killer cells, and neutrophils express low affinity IgG receptor (FcǄRIIA, FcǄRIIC, and 
FcǄRIIIB, respectively) that are not expressed in mouse (Finkelman et al., 2005). 
Less antibody and antigen are required to trigger IgE dependent anaphylaxis then IgG 
mediated anaphylaxis. IgG and IgA blocking antibodies inhibit the ability of small quantities 
of antigen to induce IgE dependent anaphylaxis by neutralizing antigen before it can cross link 
mast cell associated IgE. IgG antibodies also inhibit IgE-dependent anaphylaxis by mediating 
an interaction between FcεRI and FcǄRIIb on mast cells. In mice the predominant determinants 
that influence whether IgE dependent anaphylaxis is induced appear to be the quantity of 
antigen specific IgG antibody produced and the quantity of antigen used to challenge 
immunized mice. This suggests that IgG antibodies, in addition to mediating IgE- independent 
anaphylaxis, can block IgE-dependent anaphylaxis and provide the rationale for investigating 
the function of blocking antibody. Gastrointestinal anaphylaxis is induced by IgE/ FcεRI/mast 
cell/PAF plus serotonin pathway and can cause systemic symptoms if levels of blocking 
antibodies are low (Finkelman et al., 2005).  
3.2 Cytokines  
The development and severity of anaphylaxis depend not only on the presence of the 
required IgE or IgG antibodies, inflammatory cells that express receptor for these antibodies 
and mediators that are released by these cells but also on the responsiveness of cells that are 
targeted by these mediators. This last factor is influenced by IL-4 and IL-13, cytokines that 
are also important in the initial generation of the antibody and inflammatory cell responses 
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that mediate anaphylaxis to a considerable extent. These effects depend on IL-4Rǂ-
dependent IL4/IL13 activation of transcription factor signal transducer and activator of 
transcription 6 and thus likely depend on new gene expression and protein synthesis even 
though they develop within 1-2 hours after mice are treated with either cytokine. The most 
dramatic and rapid effect of IL-4 on anaphylaxis is a 3-to-6 fold enhancement of 
responsiveness of targeted cells to vasoactive mediators, including histamine, serotonin, 
PAF and cysteinyl lekotrienes (Finkelman et al., 2005). 
4. Clinical aspects  
Currently, there is no universally accepted clinical definition of anaphylaxis. Because of 
large variability in presenting clinical signs and symptoms, a clear definition of anaphylaxis 
is difficult. It is likely that anaphylaxis is under diagnosed, especially if it is a patient’s first 
episode, if there is a hidden or previously unrecognized trigger, or if symptoms are mild, 
transient, or skin signs are absent. Patients might not be able to describe their symptoms if 
awareness, recognition, and judgment are impaired or if they are dyspneic or becoming 
unconscious. Symptoms may be suppressed by other medications such as first-generation 
H1- antihistamines. Health care providers may fail to recognize symptoms of anaphylaxis 
without obtaining a detailed history and full physical examination. Even after a detailed 
history and examination, the diagnosis may be overlooked when hives or other skin 
manifestations are absent. The guidelines published in 2006 by the National Institute of 
Allergy and Infectious Disease (NIAID) and the Food Allergy and Anaphylaxis Network 
(FAAN) have partially responded to this difficulty (Sampson et al., 2006) (Table 1). 
However, new large studies are necessary to evaluate current situation. 
For the diagnosis of anaphylaxis, a detailed and comprehensive clinical history is essential. 
Such a history may disclose exposure to potential triggering agents or events, time elapsed 
between exposure and symptom onset, and evolution of the episode over minutes or hours. 
5. Anaphylaxis triggers 
The triggering factors of anaphylaxis are listed on Table 2. Foods, medications, and venom 
continue to be leading causes of anaphylaxis (Boden & Burks, 2011). 
5.1 Foods 
Food allergy is the most common trigger of children presenting with anaphylaxis (Boden & 
Burks, 2011). Although most episodes of food-induced anaphylaxis occur within minutes of 
ingestion, anaphylaxis triggered by mammalian meat may be delayed by several hours. 
Although, the most common food triggers are reported to be peanut, tree nuts, shellfish, 
fish, milk, egg, and sesame; there are important variations between the populations from 
different geographic regions (Sicherer & Sampson, 2006). Any food can potentially trigger 
anaphylaxis, including previously unrecognized triggers, or some fresh red meats 
containing carbohydrates. Food triggers can be hidden (eg, substituted foods, cross-reacting 
foods, and cross-contacting foods). Food triggers also include additives, such as spices, 
vegetable gums, and colorants (eg, carmine [cochineal]); contaminants, such as dust mites; 
and parasites, such as the live sea fish nematode Anisakis simplex. Although some food 
allergies resolve with age others persist. An estimated 80% of children with anaphylaxis to 
milk or egg are able to tolerate ingestion by age 16 years (Sampson & Burks, 2009).  
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Anaphylaxis is highly likely when any 1 of the following 3 criteria is fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, and swollen lips-tongue-uvula) 
AND at least 1 of the following: 
A. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia) 
B. Reduced blood pressure or associated symptoms of end-organ dysfunction (eg, 
hypotonia [collapse], syncope, incontinence) 
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that 
patient (minutes to several hours): 
A. Involvement of the skin–mucosal tissue (eg, generalized hives, itch-flush, swollen lips-
tongue-uvula) 
B. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia) 
C. Reduced blood pressure or associated symptoms (eg, hypotonia [collapse], syncope, 
incontinence) 
D. Persistent gastrointestinal symptoms (eg, cramping abdominal pain, vomiting) 
3. Reduced blood pressure after exposure to a known allergen for that patient (minutes to 
several hours): 
A. Infants and children: low systolic blood pressure (age-specific) or greater than 30% 
decrease in systolic blood pressure 
B. Adults: systolic blood pressure of less than 90 mm Hg or greater than 30% decrease from 
that person’s baseline 
Table 1. Clinical criteria for diagnosing anaphylaxis (Sampson et al., 2006 with permission) 
 
Immunologic mechanisms (IgE dependent) 
Foods and food additives 
Medications 
Venoms, such as stinging insects (Hymenoptera) 
Natural rubber latex 
Occupational allergens 
Seminal fluid (prostate-specific antigen) 
Inhalants, such as horse, hamster, and other animal danders and grass pollen (rare) 
Radiocontrast media 
Immunologic mechanisms (IgE independent, formerly classified as anaphylactoid reactions) 
Dextran, such as high-molecular-weight iron dextran 
Infliximab 
Nonimmunologic mechanisms 
Physical factors, such as exercise, cold, heat, and sunlight/UV radiation 
Ethanol 
Medications, such as opioids 
Idiopathic anaphylaxis 
Consider the possibility of hidden or previously unrecognized allergens 
Consider the possibility of mastocytosis/clonal mast cell disorder 
Table 2. Mechanisms and triggers of anaphylaxis in the community (Simons, 2010 with 
permission) 
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5.2 Drugs 
Many drugs may induce anaphylaxis as a consequence of drug allergy/hypersensitivity. 
The parenteral use of drugs increases the risk and severity of anaphylactic reactions, and 
most fatal reactions have occurred with intramuscular or intravenous administration (Chiu 
& Kelly, 2005). Although drug related anaphylaxis may occur at any age , it is particularly 
common in middle-aged and older adults. Atopy appears to be associated with a 
substantially increased risk of serious allergic reactions (including anaphylaxis) once an IgE 
antibody response to any drug has developed (Lieberman et al., 2010). Antibiotics, 
especially ǃ-lactam antibiotics including penicillin, semi-synthetic penicillins (eg, 
amoxicillin), cephalosporins, carbapenems (eg, imipenem), monobactams (eg, aztreonam), 
and carbecephems, and nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, 
ibuprofen, and other agents, are the most often implicated drugs. In the retrospective review 
of pediatric cases of anaphylaxis, the incidence of drug-induced anaphylaxis was 11%, with 
nonsteroidal anti-inflammatory drugs causing 50%, antibiotics 40%, and muscle relaxants 
10% of reactions (Novembre et al., 1998). In another study, the incidence of medications 
inducing anaphylaxis was 16%, with antibiotics causing 9%, and other drugs causing 7% of 
reactions (Dibs & Baker, 1997). In a review of fatal reactions, over four fifths of victims of 
fatal drug anaphylaxis had no previous awareness or indication of their drug allergy (Chiu 
and Kelly, 2005). Other common drugs that cause such reactions are insulin, enzymes 
(streptokinase and chymopapain), heterologous antisera (equine antitoxins and, 
antilymphocyte globulin), monoclonal antibodies (such as cetuximab, infliximab, and 
omalizumab), protamine, and heparin. However a great number of medications are known 
to cause anaphylactic reactions including chemotherapeutic agents, anesthetic agents, 
radioconrast media etc. Vaccines to prevent infectious diseases seldom trigger anaphylaxis 
(Simons, 2010). Allergic Type 1 reactions also have been reported after exposure to 
excipients such as eugenol, carmine, vegetable gums, paraben, thiomerosal, sodium 
metabisulfite, formaldehyde, and sulfonechloramide. 
5.3 Venom 
Hymenoptera stings can cause systemic and occasionally fatal anaphylaxis (Bilo & Bonifazi, 
2009). Epidemiological population-based studies over the last decade show a prevalence of 
systemic reaction from hymenoptera stings ranging from 0.3% to 8.9%, with the lowest 
occurrence in children (Chiu & Kelly, 2005). Order Hymenoptera, family Apidae 
[honeybees]; family Vespidae [eg, yellow jackets, yellow hornets, white-faced hornets, and 
paper wasps]; and family Formicidae [eg, ants]) are well known causes. Factors determining 
the severity of reaction to hymenoptera sting include history of previous severe systemic 
reaction, insect type, older age, pre-existing cardiovascular and respiratory disease, and use 
of some medications. Mastocytosis and monoclonal mast cell activation syndrome are a risk 
factor for severe systemic reactions in allergic patients (Brockow & Ring, 2011). 
5.4 Latex 
Latex-induced anaphylaxis is due to IgE-mediated mechanisms and may occur in latex 
sensitive individuals due to direct contact with latex, usually gloves, or instruments, or with 
aerosolization of latex antigen adherent to the cornstarch powder of latex gloves (Lieberman 
et al., 2010). Anaphylaxis to natural rubber latex (NRL) became one of the most pervasive 
problems in medical and surgical care in the early 1990s in children with spina bifida (Chiu 
www.intechopen.com
 
Anaphylaxis: Etiology, Clinical Manifestations, Diagnosis and Management 
 
173 
& Kelly, 2005). Latex reactions may occur immediately with latex contact or may be delayed 
from 30 to 60 minutes. Latex has been reported to account for up to 17% of intraoperative 
anaphylaxis (Lieberman et al., 2010). Intraoperative latex anaphylaxis may be related to the 
administration of drug through a latex port prior to surgery, or during the surgical 
procedure itself. Latex reactions have also been reported to occur during dental procedures 
from latex gloves or dams, during obstetrical or gynecologic examinations and during latex 
condom use. Spina bifida patients are potentially at risk during each surgical procedure 
because of the number of procedures they undergo. Latex sensitization is due to IgE-
mediated reactivity to any number of antigens from Hevea brasiliensis, the source of latex. 
Sensitization occurs in up to 12 percent of health care workers, up to 75 percent of patients 
with spina bifida and in patients undergoing multiple surgical procedures (Lieberman et al., 
2010).  
5.5 Perioperative anaphylaxis 
The incidence of anaphylaxis during anesthesia has been reported to range from 1 in 4000 to 
1 in 25,000 (Lieberman et al., 2005). The causes of anaphylaxis in this setting are varied, as 
are the mechanisms responsible for the reaction. The most common cause of anaphylaxis 
during general anesthesia or postoperatively is neuromuscular blocking agents (muscle 
relaxants), which are responsible for sixty to seventy percent of episodes of anaphylaxis 
occurring during this period. Most of the muscle relaxants cause direct release of mast cell 
histamine without the requirement for specific antibody. However, life-threatening 
reactions usually are IgE- mediated. The tertiary or quaternary ammonium group, common 
to all muscle relaxants, is likely the immunodominant determinant recognized by IgE. The 
antigenicity of the shared ammonium structures may be responsible for cross-reactivity 
among the muscle relaxants. Cross-reactivity occurs most consistently between 
pancuronium and vecuronium. Cross-reactions also may occur between muscle relaxants 
and other classes of pharmaceuticals, based upon in vitro inhibition of specific-IgE binding 
to the muscle relaxants. Agents that potentially cross-react with muscle relaxants include: 
acetylcholine, choline, morphine, neostigmine, and pentolinium. Cross-inhibition suggests 
that previous exposure to these non-anesthetic drugs may sensitize individuals to muscle-
relaxing agents, resulting in reactions among patients without prior anesthesia (Lieberman 
et al., 2005). 
5.6 Exercise anaphylaxis 
In some individuals anaphylaxis can be triggered by exercise (exercise-induced anaphylaxis 
EIA); this phenomenon usually preceded by a causative food ingestion (food-dependent, 
exercise-induced anaphylaxis (FDEIA) (Barg et al., 2011) . Both are rare but potentially life-
threatening clinical syndromes. The symptoms of FDEIA may vary in severity but, 
reassuringly, fatalities are rare. EIA occurs in all ages, in both sexes, and is more common in 
atopic individuals. Typical early signs and symptoms begin a few minutes into exercise, and 
include diffuse warmth, flushing, pruritus, urticaria, and fatigue. If exercise continues, there 
may be progression to angioedema of the face and extremities, gastrointestinal symptoms, 
laryngeal edema, hypotension, or collapse. Wheezing can occur, although it is less common 
than other symptoms. Some patients experience disabling headache that persists for several 
days after an episode. Attacks occur sporadically and unpredictably, even though most 
patients with this disorder exercise regularly. Vigorous exercises, such as jogging, racquet 
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sports, dancing, and aerobics, are most often implicated, although lower levels of exertion, 
such as brisk walking or yard work, are capable of triggering attacks in some patients. 
Cessation of exercise usually results in improvement or resolution of symptoms, although, 
patients often do not instinctively stop exercising when they first experience symptoms. 
Instead, many try to run for help or sprint home, and this precipitates a dramatic worsening 
of symptoms. Although wheat is the most commonly reported food allergen associated with 
FDEIA many other food allergens such as grains, nuts, and seafood, have also been reported 
(Barg et al., 2011). 
5.7 Idiopathic anaphylaxis 
Idiopathic anaphylaxis is diagnosed when no triggers can be identified based on history, 
skin tests are negative, and serum specific IgE levels are absent or undetectable 
(Greenberger, 2007). Before this diagnosis is made, however, the possibility of a hidden or 
previously unrecognized trigger should be ruled out and the patients should be evaluated 
for mastocytosis and clonal mast cell disorders. Idiopathic anaphylaxis has been classified 
into two categories. When there is a sudden episode that includes urticaria and angioedema 
associated with acute bronchoconstriction, voice change or stridor, syncope or proven 
hypotension with or without abdominal pain and diarrrhea, it is then considered as 
idiopathic anaphylaxis generalized (IA-G). Anaphylaxis that is characterized by marked 
upper airway obstruction attributable to massive tongue enlargement or a severely 
edematous larynx or pharynx is categorized as anaphylaxis angioedema (IA-A) 
(Greenberger, 2007).  
5.8 Mastocytocic and anaphylaxis  
In adults with mastocytosis, the cumulative prevalence of anaphylaxis has been reported to 
be 22% to 49%, and in children 6% to 9%. Those with systemic disease have an increased risk 
of anaphylaxis as compared with patients with cutaneous disease only. As in patients 
without mastocytosis, the most frequently reported elicitors of anaphylaxis are insect 
venoms, drugs, and food. Severe and fatal reactions to hymenoptera venom have been 
described in patients with mastocytosis (Brockow & Ring, 2011). 
A variety of drugs have been reported to elicit anaphylaxis in patients with mastocytosis. 
Every year, reports have been published regarding patients with mastocytosis in whom the 
diagnosis of systemic mastocytosis was made following anaphylaxis to muscle relaxants or 
other drugs used during general anesthesia. Other medications leading to reactions in 
patients with mastocytosis are opiates (including morphine and codeine), acetylsalicylic 
acid, other NSAIDs, antibiotics, and radiocontrast media. In some patients with 
mastocytosis, anaphylaxis remains idiopathic despite an extensive search for elicitors 
(Brockow & Ring, 2011). 
The intensity of anaphylaxis in patients with mastocytosis has been described to be 
particularly severe. Among 55 patients with insect sting allergy and confirmed mastocytosis, 
81% experienced severe anaphylaxis with shock or cardiopulmonary arrest (Brockow & 
Metcalfe, 2010). In another study in which the severity of anaphylaxis was rated, 60% of 
patients reported severe symptoms and 43% experienced loss of consciousness. Fatal 
reactions may occur. This is in agreement with the observation that baseline serum tryptase 
levels are the best known predictor of the severity of anaphylaxis in insect sting–allergic 
patients (Brockow & Ring, 2011) . 
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5.9 Rare causes of anaphylaxis 
Although rare, anaphylaxis due to coital exposure to human seminal fluid is a known 
occurrence. Since the initial report in 1958, approximately 30 cases of seminal fluid induced 
anaphylaxis have been described. All reactions have occurred in female patients during or 
after sexual intercourse. The vast majority of such reactions are caused by IgE-mediated 
sensitization to human seminal plasma proteins with molecular weights ranging from 12-75 
kD (Lieberman et al., 2010).  
Subcutaneous allergen immunotherapy (AIT) injections may rarely cause systemic reactions. 
Its rate has been estimated at 0.25-1.3%. Fatal anaphylaxis to AIT injections occurs at an 
estimated rate of 1 in 2.5 million injections and near-fatal anaphylactic reactions at a rate of 1 
in every 1 million injections. Patients with asthma, particularly poorly controlled asthma are 
at higher risk for serious systemic reactions to AIT injections (Lieberman et al., 2005). 
In the patients having anaphylaxis attacks without any apparent trigger hydatid cyst 
ruptures must be kept in mind. Hydatid cysts can rupture as a result of trauma or 
sometimes spontaneously, and anaphylaxis can be a complication. However, several case 
reports indicate that anaphylaxis can also occur without macroscopic hydatid cyst rupture 
(Gelincik et al., 2007). 
6. Clinical presentation  
Although most definitions specify the need for more than one organ system involvement in 
the syndrome, it is more important to understand the systemic nature of the clinical 
symptoms. The first symptoms and signs of anaphylaxis often appear within seconds to 
minutes after exposure to an offending trigger, however sometimes they may develop later. 
Late phase or biphasic reactions could also arise 8-12 hours after the initial attack 
(Lieberman et al., 2010). Each exposure to antigen is unique, and past episodes of 
anaphylaxis do not predict future events (Boden & Burks, 2011). Among individuals 
recognized as having anaphylaxis, typical initial symptoms are palmar and/or plantar itch 
with or without urticaria and/or angioedema. Target organs include skin (90% of episodes), 
respiratory tract (70%), gastrointestinal tract (30% to 45%), cardiovascular system (10% to 
45%), and central nervous system (CNS; 10% to 15%) (Simons, 2008). Accordingly, there 
may be nausea, abdominal pain, vomiting, or diarrhea. There may also be 
rhinoconjunctivitis, obstructive respiratory symptoms, tachycardia, arrhythmia, altered 
mental state, and fainting. Severe respiratory and cardiovascular signs and symptoms such 
as arterial hypotension and cardiovascular collapse may be the primary manifestations, 
particularly in perioperative reactions (Schnyder, 2009). 
Urticaria and angioedema are the most common and usually the first manifestations of 
anaphylaxis (Greenberger, 2006). Angioedema was found in 40% and urticaria in 49.3% of 
142 patients presenting to an ER with anaphylaxis (Brown et al., 2001). Laryngeal edema 
was present in 25% of such patients. In 67 patients referred to an outpatient service for 
evaluation of anaphylaxis, 44.8% of patients had experienced angioedema compared with 
58.2% for urticaria. Dyspnea, which may have included oropharyngeal or laryngeal 
swelling, was noted in 59.7% of patients (Thong et al., 2005). In patients with idiopathic 
anaphylaxis, 335 patients, ages 5 to 83, were categorized based on whether the acute episode 
was generalized (urticaria or angioedema with bronchospasm, hypotension, syncope, or 
gastrointestinal symptoms with or without upper airway obstruction) or angioedema 
(urticaria or angioedema with upper airway compromise without other systemic symptoms 
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such as shock) (Ditto et al., 1996). From the 335 patients, 201 (60%) were classified as IA-G 
and 119 (35.5%) were designated as IA-A. In this series, urticaria or angioedema occurred in 
all 335 patients, but anaphylaxis, implying a life-threatening emergency, involved 
angioedema of the upper airway in over a third of patients. Indeed, these patients had 
experienced laryngeal or pharyngeal edema or ‘‘massive tongue edema’’. Perhaps, most 
persuasively, in this series of 335 patients, upper airway obstruction occurred in 210 (63%) 
patients (Ditto et al., 1996).  
However, skin and mucosal symptoms and signs are absent or unrecognized in 10% to 20% of 
all anaphylactic episodes (Simons, 2010). These are rather more severe forms of anaphylaxis 
arising suddenly with either respiratory compromises or cardiovascular collapse. The lack of 
cutaneous signs reflects that anaphylaxis episode is likely to become fatal.  
There are some differences in the presentation of anaphylaxis in the pediatric population 
compared with the adult population, including smaller numbers having cardiovascular 
signs and symptoms (21% compared with 41%). Other features noted in pediatric 
anaphylaxis include skin and respiratory signs appearing with an earlier onset compared 
with gastrointestinal and cardiovascular signs. Most children had a personal history of 
atopy (Dibbs & Baker, 1997). 
The symptoms and signs of anaphylaxis are shown in Table 3. 
 
Cutaneous/subcutaneous/mucosal tissue 
Flushing, pruritus, hives (urticaria), swelling, morbilliform rash, pilor erection 
Periorbital pruritus, erythema and swelling, conjunctival erythema, tearing 
Pruritus and swelling of lips, tongue, uvula/palate 
Pruritus in the external auditory canals 
Pruritus of genitalia, palms, soles 
Respiratory 
Nose: pruritus, congestion, rhinorrhea, sneezing 
Larynx: pruritus and tightness in the throat, dysphonia and hoarseness, dry staccato cough, 
stridor, dysphagia 
Lung: shortness of breath, chest tightness, deep cough, wheezing/bronchospasm 
(decreased peak expiratory flow) 
Cyanosis 
Gastrointestinal 
Nausea, cramping abdominal pain, vomiting (stringy mucus), diarrhea 
Cardiovascular 
Chest pain, palpitations, tachycardia, bradycardia, or other dysrhythmia 
Feeling faint, altered mental status, hypotension, loss of sphincter control, shock, cardiac arrest 
CNS 
Aura of impending doom, uneasiness, throbbing headache, dizziness, confusion, tunnel vision; 
in infants and children, sudden behavioral changes, such as irritability, cessation of play, and 
clinging to parent 
Other 
Metallic taste in the mouth 
Dysphagia 
Uterine contractions in postpubertal female patients 
Table 3. Symptoms and signs of anaphylaxis (Simons, 2010 with permission) 
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7. Laboratory tests 
No optimal and readily available laboratory test can confirm the clinical diagnosis of an 
anaphylactic episode. Nevertheless, in some patients the clinical diagnosis of anaphylaxis can 
be confirmed by means of a blood test; for example, an increased plasma histamine level or 
serum total tryptase level (Simons, 2010). These tests are not specific for anaphylaxis. Plasma 
histamine levels should optimally be measured 15 to 60 minutes after onset of symptoms of 
anaphylaxis. Special handling of the blood sample is required. Histamine and its metabolite, 
N-methylhistamine, can also be measured in a 24-hour urine sample. Because tryptase is 
selectively and abundantly produced by mast cells, tryptase levels in biologic fluids should 
provide a more precise measure of local or systemic involvement of these cells than is possible 
to ascertain by clinical presentation or documentation of antigen-specific IgE. Basophils, the 
only other cell type that normally expresses tryptase, contain approximately 1/500th the 
amount mature ǃ tryptase levels generally reflect the magnitude of mast cell activation and are 
elevated during most cases of systemic anaphylaxis, particularly with parenteral exposure to 
the inciting agent (Schwartz, 2006). Not all hypotensive reactions that clinically seem to be 
anaphylactic are associated with elevated levels of mature tryptase, however. For example, 
victims of fatal and near-fatal food-induced anaphylaxis often show no mature tryptase 
elevation, raising the possibility that some of these events may not be dependent on mast cell 
activation. Basophils have been suggested as an alternative effector cell, but direct evidence for 
this has not yet emerged. Other considerations might include overproduction through non-
mast cell pathways of vasoactive mediators, such as complement anaphylatoxins, kinins, or 
lipids (Schwartz, 2006). 
Serum total tryptase levels should optimally be measured from 15 minutes to 3 hours after 
onset of symptoms. No special handling of the blood sample is required. The total tryptase 
level is typically increased in patients with anaphylaxis triggered by an injected medication 
or an insect sting and in those with hypotension and shock but is less likely to be increased 
in those with anaphylaxis triggered by food or in those who are normotensive. Serial 
measurements of serum total tryptase and comparison with baseline levels obtained after 
the acute episode or available in stored serum might be more helpful than measurement at a 
single point in time. Other biomarkers reported to be useful in confirming an acute episode 
of anaphylaxis include serum mature ǃ-tryptase; mast cell carboxypeptidase A3; chymase; 
platelet-activating factor; bradykinin; C-reactive protein; cytokines, such as IL-2, IL-6, IL-10, 
IL-33, and TNF-receptor I; and urinary cysteinyl leukotriene E4 and 9-a-11-b prostaglandin 
F2 (Simons, 2010).  
It was shown that serum PAF levels were directly correlated and serum PAF 
acetylhydrolase activity was inversely correlated with the severity of anaphylaxis. PAF 
acetylhydrolase activity was significantly lower in patients with fatal anaphylactic reactions 
to peanuts than in patients in any of the control groups. Failure of PAF acetylhydrolase to 
inactivate PAF may contribute to the severity of anaphylaxis (Vadas et al., 2008). 
8. Diagnosis 
All individuals who have had a known or suspected anaphylactic episode require a careful 
and complete review of their clinical history. This history may elicit manifestations such as 
urticaria, angioedema, flushing, pruritus, upper airway obstruction, gastrointestinal 
symptoms, syncope, hypotension, lower airway obstruction, and/or other less common 
manifestations (Lieberman et al., 2010). 
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Other conditions that should be considered in the differential diagnosis include: (1) 
vasodepressor (vasovagal/neuro-cardiogenic) syncope; (2) syndromes that can be 
associated with flushing (e.g., metastatic carcinoid); (3) postprandial syndromes (e.g., 
scombroid poisoning); (4) systemic mastocytosis; (5) psychiatric disorders that can mimic 
anaphylaxis such as panic attacks or vocal cord dysfunction syndrome; (6) angioedema (e.g., 
hereditary angioedema); (7) other causes of shock (e.g., cardiogenic); and (8) other 
cardiovascular or respiratory events (Lieberman et al., 2005). 
The history is the most important tool to establish the cause of anaphylaxis and takes 
precedence over diagnostic tests. A detailed history of all food consumed and drugs taken 
over the four to six hours prior to the episode should be obtained. In addition, the labels for 
all packaged foods ingested by the patient in this period of time should be reviewed since a 
substance added to the food could be responsible. A history of any preceding bite or sting 
should be obtained. The patient’s activities (e.g., exercise, sexual activity) preceding the 
event should be reviewed. Patient diaries may be a useful adjunct in confirming or 
identifying the cause of anaphylaxis (Lieberman et al., 2010).  
A detailed history of all potential causes should be obtained. This includes a list of 
ingestants consumed and/or medications taken within six hours of the event, any sting or 
bite occurring prior to the event, if the event occurred during exercise, location of the event 
(e.g., work versus home), and whether or not the event was related to exposure to heat, cold, 
or occurred during sexual activity. The patient’s atopic status should be noted since food-
induced, seminal fluid and idiopathic anaphylaxis are more common in atopic than non-
atopic individuals. In women, the history should include any relationship between the 
attack and their menstrual cycle. A return of symptoms following a remission should be 
noted since this may indicate a late phase reaction, which might require a prolonged period 
of observation if subsequent events occur (Lieberman et al., 2010).  
8.1 Confirmation of the triggers of anaphylaxis 
The next step in the evaluation of a patient experienced anaphylaxis is confirmation of the 
trigger or triggers identified or suspected through the history (Simons, 2010). So that the 
relevant specific trigger or triggers can be avoided and recurrences of anaphylaxis can be 
prevented. Skin tests should be performed with validated instruments, techniques, and 
recording systems, preferably at least 3 to 4 weeks after the anaphylactic episode, to allow 
time for rearming of skin mast cells and recovery of mast cell releasability. When possible, 
standardized extracts for skin testing should be used, although occasionally fresh food 
extracts will be superior to available standardized extracts. If the skin testing extract has not 
been standardized (e.g., latex, protamine, or antibiotics other than penicillin), the clinical 
relevance of the results may be uncertain. Skin tests or in vitro tests can determine the 
presence of specific IgE antibodies to foods, medications (e.g., penicillin and insulin), and 
stinging insects as a cause of anaphylaxis (Lieberman et al., 2010). Measurement of allergen-
specific IgE levels by using a quantitative method can be performed at any time during or 
after the acute anaphylactic episode; however, if the blood sample is obtained during or 
shortly after the episode from patients who have received intravenous fluid resuscitation, 
levels can be falsely undetectable or low because of the dilutional effect on circulating IgE. 
Negative tests for sensitization to a trigger in a patient with a convincing history of 
anaphylaxis from that trigger should be repeated weeks or months later. It is important to 
note that both positive skin tests and increased specific IgE levels indicate sensitization to 
the allergens tested but are not diagnostic of anaphylaxis or any other disease (Lieberman et 
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al., 2010). The clinical significance of skin testing or in vitro test depends on the ability to 
correlate the results of such testing with the patient’s history. If tests for specific IgE 
antibodies (i.e., skin tests, in vitro tests, or both) do not provide conclusive evidence of the 
cause of anaphylaxis, challenge with the suspected agent can be considered. If indicated, 
incremental challenge/provocation tests should be conducted in appropriately equipped 
health care facilities by professionals trained and experienced in patient selection, timing of 
the challenge, use of challenge protocols, and diagnosing and treating anaphylaxis. Before a 
challenge is performed, the potential risks and benefits should be discussed with the patient 
(or, for children, the caregivers) and documented in the medical record. Challenge 
procedures may also be appropriate in patients who develop non-IgE-mediated reactions 
(e.g., reactions to aspirin (ASA) or other nonsteroidal anti-inflammatory drugs. Challenge 
with suspected agents must be done carefully by individuals knowledgeable in the 
challenge procedure and with expertise in managing reactions to the challenge agent if they 
should occur (Lieberman et al., 2010). 
8.2 Assessment of patients with food-triggered anaphylaxis  
Skin prick tests with foods that elicit a wheal of 3 mm larger than that caused by the negative 
control (eg. saline) are considered positive (Simons, 2010). Commercially available food 
allergen extracts do not contain standardized allergens. Some food allergens, such as fruits and 
vegetables, are labile and degrade in glycerinated extracts during manufacture and storage; 
therefore skin prick tests with these allergens are often performed with fresh foods. 
Intradermal tests to foods are contraindicated because of lack of specificity (false-positive 
tests) and their potential for triggering anaphylaxis (Lieberman et al., 2010). An exception to 
this might be use of intradermal tests to assess sensitization to fresh meat containing the 
carbohydrate galactose-alpha-1,3-galactose. In food-sensitized patients specific IgE levels 
have predictive values for positive (failed) or negative (passed) food challenge tests. 
Allergen-specific IgE levels with greater than 95% predictive risk values of a positive (failed) 
food challenge result have been identified by using the ImmunoCAP (Phadia, Uppsala, 
Sweden). These levels are defined for cow’s milk (15 kU/L), egg (7 kU/L), peanut (14 
kU/L), tree nuts (15 kU/L), and fish (20 kU/L); in infants lower values have been 
established for milk (5 kU/L) and egg (2 kU/L) (Boden & Burks, 2011). Predictive values for 
allergen-specific IgE levels potentially differ from one immunoassay to another, and this can 
affect management decisions. 
A positive skin test, an increased serum IgE level, or both to a specific food document 
sensitization to that food. Such tests are not diagnostic of anaphylaxis because sensitization 
to 1 or more food allergens is common in the general population of healthy people who 
have no history of anaphylaxis. For example, 60% of young people have a positive skin prick 
test to 1 or more foods, yet most of those with positive tests have never experienced 
anaphylaxis from a food. In addition, although positive skin tests and increased allergen-
specific IgE levels correlate with an increased probability of clinical reactivity to specific 
foods, the results of these tests do not necessarily correlate with the risk of future 
anaphylactic episodes or with the severity of such episodes (Simons, 2010). 
Oral food challenge testing is accepted as a gold standard for detection of a food 
allergy/hypersensitivity (Sampson & Burks, 2009). Patients with a convincing history of 
anaphylaxis to a specific food and evidence of sensitization to that food should not undergo 
oral food challenge tests because of their high risk of anaphylaxis from such tests. Others, 
such as those with an equivocal history, low or moderate evidence of sensitization, or both, 
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might benefit from a physician-monitored incremental oral food challenge. A positive 
(failed) challenge provides a basis for continued avoidance of the food. A negative (passed) 
challenge allows introduction or reintroduction of the specific food into the patient’s diet.  
8.3 Assessment of medication- or biological agent –triggered anaphylaxis  
Any medication or biological agent can potentially trigger anaphylaxis. In cases with severe  
anaphylactic reactions, it is advisable to first perform skin tests with the presumably 
causative drugs only by prick (Schnyder & Pichler, 2009). If responses are negative and the 
involved drug is available as a parenteral formulation, negative skin tests do not have 
sufficient sensitivity to exclude an immune-mediated hypersensitivity in the case of a 
suggestive history. For most agents, the antigenic determinants have not been characterized 
or validated; indeed, the relevant immunogenic prodrugs, haptens, metabolites, and 
unidentified degradation products or contaminants are often unknown. For most 
medications, with the exception of some ǃ-lactam antibiotics, appropriate reagents are not 
commercially available for use in skin tests, measurement of medication-specific IgE levels, 
or other in vitro tests. In penicillin allergies, standardized preparations with 
penicilloylpolylysine and minor determinant mixture may be used (Lieberman et al., 2010). 
Penicillin allergy may also be evaluated by in vitro tests for specific IgEs; however, these 
tests have a low sensitivity. Additionally, assays for a few drugs such as suxamethonium, 
rocuronium, morphine, sulfamethoxazole, and chlorhexidine, are offered, some with 
potentially higher sensitivity (Schnyder, 2009). A further in vitro test to identify the relevant 
drug may be the basophil activation test. This test is based on flow cytometric quantification 
of drug-induced CD63 expression or CD203c up-regulation or measurement of sulfo-
leukotriene release by ELISA. The sensitivity in IgE-mediated reactions appears to be 
superior to CAP-based IgE determinations and comparable with skin tests. Customized tests 
and physician-monitored challenge/provocation tests performed in specialized centers 
therefore play a central role in assessment of patients with a history of anaphylaxis triggered 
by a medication. A drug provocation test (DPT) is defined as controlled administration of a 
drug to diagnose immune-mediated and non–immune-mediated drug hypersensitivity. Its 
advantage is that it permits testing of a patient with his or her individual metabolism and 
immunogenetic background. A DPT reproduces not only symptoms of allergy but other 
adverse clinical manifestations, irrespective of their mechanism. A DPT is currently the 
‘‘gold standard,’’ but its use is limited by the possibility of severe and uncontrollable relapse 
of the reaction (Aberer et al., 2010). Therefore, a DPT should be reserved for specific 
situations when a significant drug is suspected to have provoked an intolerance reaction 
and alternative test methods have failed to yield conclusive results. The patient being tested 
has to be in stable condition, and an anticipated positive reaction must be controllable by 
adequate measures. Because of these restrictions, only physicians experienced in drug 
allergy should perform this test. The two main indications for a DPT with the suspected 
drug are the following: to exclude hypersensitivity in the presence of unconvincing histories 
of drug hypersensitivity or in patients with nonspecific conditions, such as subjective 
symptoms under local anesthesia, or to establish a distinct diagnosis in suggestive histories 
of drug hypersensitivity with inconclusive, negative, or nonavailable allergy test results. A 
positive DPT result optimizes the avoidance of certain drugs, whereas a negative one 
permits the clinician to rule out a false diagnosis of drug hypersensitivity. 
For assessment of anaphylaxis triggered by vaccines to prevent allergic diseases, skin prick 
tests should be performed not only with the immunizing agent but also with the relevant 
www.intechopen.com
 
Anaphylaxis: Etiology, Clinical Manifestations, Diagnosis and Management 
 
181 
excipients in the culprit vaccine, such as gelatin in measles vaccines or egg in some influenza 
vaccines and in yellow fever vaccine (Simons, 2010). 
8.4 Assessment of stinging insect-triggered anaphylaxis  
Standardized Hymenoptera venoms, such as honeybee, yellow jacket, yellow hornet, white-
faced hornet, and Paper wasp, are available for skin testing. Skin prick tests, if negative, 
should be followed by intradermal tests (Bilo & Bonifazi, 2009). Use of dialyzed venoms in 
skin tests is reported to improve the identification of venom-sensitized patients (Golden et 
al., 2009). For fire ant-triggered anaphylaxis, whole-body extracts are used as skin test 
reagents. Measurements of venom-specific IgE levels are commercially available (Freeman, 
2004). Some patients with a history of Hymenoptera sting–triggered anaphylaxis have 
negative skin test responses to insect venoms but increased specific IgE levels to venoms 
and vice versa (Simons, 2010). Positive intradermal tests to stinging insect venoms, 
increased venom-specific IgE levels, or both occur in up to 28.5% of the general adult 
population, most of whom do not have systemic symptoms after an insect sting (Simons, 
2010). It is therefore critically important that the test results be interpreted in the context of 
the clinical history. In some centers additional tests used to assist in interpretation of 
positive test results include consideration of total IgE levels as well as venom-specific IgE 
levels, and measurement of basophil activation markers, such as CD63 or CD203c after 
incubation with different concentrations of venom (Simons, 2010). Conversely, venom skin 
tests might be negative and venom specific IgE levels might be absent or undetectable in 
patients with a convincing history of insect sting–triggered anaphylaxis (Simons, 2010).  
8.5 Perioperative anaphylaxis  
Skin testing may be useful to determine the safest alternative for subsequent anesthesia 
following a suspected reaction. Skin testing with neuromuscular blocking agents, hypnotics 
and opioids is used. Antibiotics frequently are administered before, during, or immediately 
after anesthesia and surgery. Allergic reactions to antibiotics, particularly anaphylaxis, may 
occur during the perioperative period. For this reason, following a suspected reaction 
during anesthesia, skin tests with antibiotics should also be done. It should be noted that 
nonimmunologic reactions are not identified by this diagnostic method. Skin testing is not 
recommended for preanesthetic screening of subjects without a history of suspected 
reactions (Lobera et al., 2008).  
8.6 Assessment of anaphylaxis triggered by natural rubber latex 
Skin prick tests should be performed with commercial latex allergens, where available, or 
with extracts of rubber products, such as natural rubber latex gloves, where commercial 
allergens are not available. In vitro tests have highly variable sensitivity and specificity 
characteristics (Lieberman et al., 2010). Consideration should be given to testing with foods 
that cross-react with latex, such as banana, kiwi, papaya, avocado, potato, and tomato. 
Latex-specific IgE antibodies can also be measured. 
8.7 Assessment of exercise-triggered anaphylaxis  
These should be done: meticulous clinical history, skin or in vitro testing for potential food 
allergen co triggers, and occasionally, documenting mast cell activation if this can be 
determined in the minutes or hours following an attack (Lieberman et al., 2010). The 
diagnosis of EIA can be confirmed by eliciting symptoms with treadmill testing. However, 
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symptoms are difficult to reproduce. The differential diagnosis includes arrhythmias and 
other cardiovascular events, but such events do not include pruritus, urticaria, angioedema, 
or upper airway obstruction. Exercise induced bronchoconstriction presents with symptoms 
that are limited to the airways. Exercise-associated gastroesophageal reflux could mimic 
mild symptoms of EIA, although, urticaria and/or pruritus are not observed (Feldweg & 
Sheffer, 2011). 
8.8 Assessment of idiopathic anaphylaxis  
When a meticulous history of antecedent exposures and events does not yield any clues 
about potential triggers and when allergen skin tests are negative and specific IgE 
measurements are absent or undetectable to selected common allergens, patients are said to 
have idiopathic anaphylaxis (Greenberger, 2007). The diagnosis of idiopathic anaphylaxis is 
based on exclusion. Before making this diagnosis, physicians should consider the possibility 
of a hidden or previously unrecognized trigger. Sensitization to a novel trigger for which 
there is no commercially available test material, can be identified through a history of the 
event and confirmed by objective tests.  
Patients with idiopathic anaphylaxis should receive careful evaluation for possible causes, 
with emphasis on the history of events in the 3 hours prior to an episode. Selective skin 
testing with foods (and if indicated to fresh food extracts) may be of value. Indolent 
systemic mastocytosis must be excluded. Consistently elevated serum tryptase levels 
suggest the presence of indolent systemic mastocytosis since the serum tryptase will be 
elevated in the absence of episodes of anaphylaxis. In contrast, serum tryptase levels will be 
normal in quiescent idiopathic anaphylaxis. A bone marrow examination may be indicated 
in patients with a diagnosis of idiopathic anaphylaxis even in the absence or elevated 
tryptase levels if salmon colored, hyperpigmented macules and papules consistent with 
urticaria pigmentosa are found (Akın et al., 2007). The differential diagnosis of idiopathic 
anaphylaxis includes hereditary angioedema or acquired C1 inhibitor deficiency. Some 
patients with idiopathic anaphylaxis present with massive enlargement of the tongue 
and/or life-threatening upper airway obstruction due to pharyngeal or laryngeal 
angioedema, but their C4 concentration is not reduced.  
9. Management  
Anaphylaxis, as a potentially life-threatening condition must be diagnosed and managed 
promptly. Although the etiology may be various or indefinite and there is lack of rapid 
diagnostic tests, the diagnosis relies mostly on clinical symptoms, therefore requires a high 
index of suspicion. Irrespective of the trigger or mechanism of anaphylaxis, the initial 
management is the same and is based on basic therapeutic agents that all healthcare 
professionals should be able to provide, even in a low resource environment (Lee & Vadas, 
2011; Simons et al., 2011). Prompt and definitive management can be life saving whereas the 
delay in the management may result in a fatal outcome (Lieberman et al., 2010). 
Anaphylaxis can potentially affect cardiovascular and respiratory systems and be presented 
as a multisystem emergency. The trigger has to be removed, if possible and the patient’s 
circulation, airway, breathing, level of consciousness, and skin should be rapidly assessed 
(Simons et al., 2011). According to the consensus of experts, in general the treatment in order 
of importance includes epinephrine (adrenaline), patient position, oxygen, intravenous 
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fluids, nebulized therapy, vasopressors, antihistamines, corticosteroids, and other agents 
(Lieberman et al., 2010). 
In a series of over 200 anaphylaxis deaths the median time from onset of symptoms to fatal 
cardiopulmonary arrest was reported as <30 minutes (Pumphrey, 2000). In the same paper 
the median times to cardiopulmonary arrest were 5 minutes after administration of a 
diagnostic or therapeutic intervention, 15 minutes after an insect sting, and 30 minutes after 
food ingestion. As soon as the need is recognized, supplemental oxygen at a flow rate of 6-8 
L/min, intravenous fluid resuscitation must be administered and the cardiopulmonary 
resuscitation with continuous chest compressions before giving rescue breathing must be 
initiated (Simons et al., 2011). Patients should be kept supine with legs raised to prevent 
death due to ‘empty vena cava/ empty ventricle syndrome’ with pulseless electrical activity 
(Pumphrey, 2003). In this syndrome patients in shock suddenly sit, stand, or are placed 
upright, the vena cava empties within seconds, and epinephrine is prevented from 
circulating the body (Pumphrey & Gowland, 2007). The patient must be kept in a 
comfortable position if vomiting or respiratory distress is present (Simons et al., 2011).  
Supplemental oxygen should be given by face mask or oropharyngeal airway to all patients 
with concomitant asthma, other chronic respiratory disease, or cardiovascular disease and 
those having prolonged reactions or those who are receiving inhaled ǃ-agonists as part of 
the treatment for anaphylaxis or repeated doses of epinephrine (Lieberman et al., 2010; 
Simons et al., 2011). Oxygen supplementation should be guided with continuous pulse 
oximetry and/or arterial blood gas determination (Lieberman et al., 2010). 
The fluid management is critical as massive fluid shifts can occur due to increased vascular 
permeability within minutes (Brown et al., 2004). Saline stays in the intravascular space 
longer than dextrose and contains no lactate which may exacerbate metabolic acidosis. 
Therefore one to 2 L of 0.9% isotonic saline as a preferred solution should be commenced as 
5-10 mL/kg in the first 5-10 minutes to an adult or 10 mL/kg to a child as soon as the need 
for it is recognized (Lieberman et al., 2010; Simons et al., 2011). The rate of administration 
should be titrated according to the blood pressure, cardiac rate and function and urine 
output. Caution should be undertaken for volume overload (Simons et al., 2011). In some 
cases fluid replacement may not be so effective when considered with other indications. It is 
possible that the replaced fluid during management can also shift from the vasculature to 
tissues. Therefore the cornerstone of management is a non-selective adrenergic agonist 
agent, epinephrine which acts on ǂ-1, ǃ-1 and ǃ-2 adrenergic receptors and is highly 
effective to reverse the clinical symptoms mainly with vasoconstriction, cardiac stimulation 
and bronchodilatation (Lee & Vadas, 2011; Simons et al., 2009a). The World Health 
Organization (WHO) classifies epinephrine as an essential medication for the treatment of 
anaphylaxis (Simons et al., 2011). The evidence base for prompt epinephrine injection in the 
initial treatment of anaphylaxis is stronger than the evidence base for the use of 
antihistamines and glucocorticoids in anaphylaxis (Simons et al., 2011). Therefore overt 
signs of distributive shock or cardiovascular compromise should not be waited to 
administer epinephrine. It is recommended that epinephrine be given as soon as possible 
(Lee & Vadas, 2011). Although there is any doubt in recognition of the clinical situation as 
anaphylaxis, it is generally better to administer epinephrine (Lieberman et al., 2010). 
Pharmacokinetic studies have shown that the intramuscular route of administration into the 
mid-anterolateral thigh (the vastus lateralis muscle) is preferable with a faster onset of 
action and more sustained levels as compared with the subcutaneous route (Lee & Vadas, 
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2011; Simons, 2009b). The rationale for intramuscular injection is that the striated muscle is 
well vascularized, facilitating rapid systemic absorption and prompt achievement of peak 
epinephrine pharmacologic effects. In contrast subcutaneous tissue consisting mostly of 
poorly vascularized adipose tissue provides the slow absorption of epinephrine with 
variable time intervals for peak pharmacologic effects (Simons, 2009b). Significantly faster 
peak plasma concentrations are achieved via the intramuscular route (8 ± 2 min) than the 
subcutaneous route of administration (34 ± 14 min) in children, and in adults (Frew, 2010). 
Intramuscular epinephrine injections into the thigh have been reported to provide more 
rapid absorption and higher plasma epinephrine levels in both children and adults than 
intramuscular or subcutaneous injections administered in the arm (Lieberman et al., 2010). 
Alternative routes of administration have been anecdotally tried. For example sublingual 
delivery of 40 mg epinephrine has been shown to lead to plasma concentrations that are not 
significantly different to those following intramuscular administration of 0.3 mg 
epinephrine (Frew, 2010). 
The recommended dose of epinephrine for children is 0.01 mg/kg body weight of a 1:1,000 
(1 mg/mL) solution, to a maximum initial dose of 0.3 mg in a 30 kg child (Simons, 2009b). In 
the recent guideline of World Allergy Organization (WAO) the same dose of epinephrine in 
adults with a maximum initial dose of 0.5 mg is recommended (Simons et al., 2011). In the 
recent Practice Parameter on the Diagnosis and Management of Anaphylaxis, the dose is 
defined as 0.2-0.5 ml of aqueous epinephrine of a 1:1,000 dilution in adults and as 
0.01mg/kg of the same dilution in children (Lieberman et al., 2010). The dose can be 
repeated every 5-15 minutes, as needed depending on the severity of the episode and the 
response to the initial injection (Lieberman et al., 2010; Simons et al., 2011). Approximately 
20% of cases in the community require a second dose because of lack of response to the first 
dose, or development of a biphasic reaction (Simons, 2009b).  
The patient has to be monitored with blood pressure, cardiac rate and function, respiratory 
status at regular intervals and oxygenation continuously, if possible (Simons et al., 2011). 
The duration of monitoring should be individualized. Patients with moderate respiratory or 
cardiovascular compromise should be monitored in a medically supervised setting for at 
least 4 hours and if indicated 8-10 hours or longer, and patients with severe or protracted 
anaphylaxis might require monitoring and interventions for days (Simons et al., 2011). 
In patients who remain hypotensive and unresponsive to intramuscular epinephrine and 
fluid resuscitation, the ones who have progressed to shock or cardiac arrest intravenous 
epinephrine is recommended (Lee & Vadas, 2011; Simons et al., 2011). Ideally, this route 
should be administered only by trained, experienced physicians who are equipped to give 
vasopressors through an infusion pump and titrate the dose frequently according to 
noninvasive continuous monitoring of cardiac rate and function. A controlled infusion is 
safer than bolus administration (Soar et al., 2008). If cardiac arrest is imminent or has 
already occurred, an intravenous bolus dose of epinephrine is indicated according to 
Resuscitation Guidelines (Simons et al., 2011). An intravenous epinephrine infusion is 
prepared by adding 1 mg (1 mL) of 1:1,000 dilution of epinephrine to 250 mL of 5% dextrose 
to yield a concentration of 4.0 µg/mL. This 1:250,000 solution is infused at a rate of 1µg/mL, 
titrated to a maximum of 10.0µg/min for adults. In children, a dosage of 0.01 mg/kg (0.1 
mL/kg of a 10,000 solution up to 10µg/min; maximum dose, 0.3 mg is administered 
(Lieberman et al., 2010). Other protocols for intravenous administration are also suggested 
(Lieberman et al., 2010). 
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Dopamine as a vasopressor agent is recommended when epinephrine and fluid 
resuscitation fail to alleviate hypotension in a dose of 2-20µg/kg/min, titrated to maintain 
systolic blood pressure greater than 90 mmHg. During cardiopulmonary resuscitation 
intravenous high-dose epinephrine is recommended. A common sequence is 1 to 3 mg 
(1:10,000 dilution) intravenous slowly administered over 3 min, 3 to 5 mg intravenous over 3 
min, and then 4-10 µg/min infusion. For children, the recommended initial resuscitation 
dosage is 0.01 mg/kg (0.1 ml/kg of a 1:10,000 solution up to 10 µg/min rate of infusion), 
repeated every 3 to 5 min for ongoing arrest. Higher subsequent dosages (0.1-0.2 mg/kg: 0.1 
ml/kg of a 1:1,000 solution) may be considered for unresponsive asystole or pulseless 
electrical activity (Lieberman et al., 2010). 
The common adverse effects of epinephrine include anxiety, dizziness, restlessness, 
headache, palpitations, tremor, and pallor and indicate that a therapeutic dose has been 
given (Lee & Vadas, 2011; Simons, 2009b). Rare side effects of epinephrine more commonly 
related with high or rapid doses of intravenous administration include ventricular 
arrhythmias, angina, myocardial infarction, pulmonary edema, hypertensive emergency, 
and intracranial haemorrhage (Lee & Vadas, 2011; Simons et al., 2011). It was demonstrated 
that the heart is the target organ of anaphylaxis and acute coronary syndrome can occur in 
anaphylaxis in the absence of epinephrine administration in patients with known coronary 
artery disease, and those in whom subclinical coronary artery disease is unmasked by the 
anaphylactic episode (Simons et al., 2011). Concerns about adverse effects, especially 
potential myocardial infarction and cardiac arrhythmias, need to be weighed against the 
cardiac risks of untreated anaphylaxis (Simons, 2009b; Simons et al., 2011). As there is no 
controlled trials mainly because of ethical concerns, there is no way to estimate the risk in 
relation to benefit of epinephrine, but on the basis of current evidence, the benefit of using 
appropriate doses of intramuscular epinephrine is likely to far exceed the risk (Sheikh et al., 
2009). According to the recent WAO guidelines epinephrine is not contraindicated in the 
treatment of anaphylaxis in patients with known or suspected cardiovascular disease, or in 
elderly patients without known coronary artery disease who are at risk of acute coronary 
syndrome only because of their age (Simons et al., 2011). However, careful monitoring and 
avoidance of an adrenaline overdose are necessary in these patients (Sheikh et al., 2009). 
In a recent systematic Cochrane review, it was emphasized that there are no absolute 
contraindications to epinephrine use in anaphylaxis and in the absence of appropriate trials, 
and suboptimal evidence, epinephrine administration is recommended to be regarded as the 
first-line treatment for the management of anaphylaxis (Sheikh et al., 2009). Some relative 
contraindications include patients using mono-amine oxidase inhibitors, tricyclic anti-
depressants, or stimulant medications or illicit substances, all of which are possibly 
increasing the risk of adverse effects of epinephrine (Lee & Vadas, 2011). Caution is needed 
in patients with recent intracranial surgery, aortic or cerebral aneurism(s), uncontrolled 
hyperthyroidism, or hypertensive emergencies (Lee & Vadas, 2011).  
H1-antihistamines are frequently used in anaphylaxis, but they cannot be substituted for 
epinephrine as first line treatment (Sheikh et al., 2007). A Cochrane systematic review of the 
literature has found no high quality evidence either for or against the use of H1-
antihistamines in anaphylaxis; therefore randomized controlled trials are needed (Sheikh et 
al., 2007). These agents do not prevent or reverse life-threatening upper and lower 
respiratory tract obstruction, hypotension or shock (Simons et al., 2009a), but they relieve 
itching, flushing, urticaria, angioedema and nasal and eye symptoms (Simons, 2009b; 
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Simons et al., 2011). As a second line medication, for example diphenhydramine 1 mg/kg, 
approximately 25-50 mg in adults, maximum 50 mg in children is recommended by slow 
intravenous infusion over 10-15 minutes. The route of administration depends on the 
severity of the attack. Only the first generation H1-antihistamines are available for 
intravenous use and they potentially increase vasodilation and hypotension if given rapidly 
(Simons et al., 2011). H2-antihistamines in combination with H1-antihistamines are 
sometimes used for anaphylaxis treatment in the US and Canada (Lieberman et al., 2010; 
Simons et al., 2011). When an oral H1-antihistamine is indicated, a low sedating medication 
such as cetirizine is preferable to a sedating H1-antihistamine (Simons et al., 2011). 
Glucagon is preferred in patients who are already using ǃ- blockers therefore experiencing a 
relative bradycardia and refractory hypotension and are not fully responding to epinephrine 
(Gallagher et al., 2011; Thomas & Crawford, 2005). It shows its effects independent of ǃ-
receptors by directly activating adenyl cyclase. The recommended dose is 1 to 5 mg in adults 
and 20-30 µg/kg (maximum of 1 mg) administered intravenously over 5 min as a bolus. The 
bolus dose can be repeated or followed by an infusion of 5-15µg/min, titrated to clinical 
response (Lieberman et al., 2010). The common side effect is emesis, particularly related 
with rapid infusion and therefore protection of the airways to prevent aspiration in severely 
drowsy patients is important (Lee & Vadas, 2011; Lieberman et al., 2010). 
A recent Cochrane systematic review concluded that there is insufficient high-quality 
evidence to either support or not to support the use of glucocorticosteroids in the 
management of anaphylaxis (Choo et al., 2010). The existing evidence consists mainly of 
retrospective studies, case reports, and other descriptive literature. The recent WAO 
anaphylaxis guideline recommends glucocorticosteroid use in anaphylaxis management as a 
second line medication. It is used to prevent biphasic or protracted symptoms, although 
there is weak evidence for it (Simons et al., 2011). It doesn’t provide rapid relief of upper or 
lower airway obstruction, shock, or other symptoms of anaphylaxis (Simons, 2009b). The 
route of administration depends on the severity of the attack (Simons et al., 2011). The 
recommended dose of methylprednisolone by WAO anaphylaxis guideline is 1-
2mg/kg/day, approximately 50-100 mg or equivalent for 3-4 days in adults, at a maximum 
dose of 50 mg in children (Lee & Vadas, 2011; Simons et al., 2011). Other guidelines 
recommend hydrocortisone, triamcinolone, prednisone by intravenous, intramuscular, or 
oral routes using different doses and dose regimens (Soar, 2005, Brown et al., 2006, Alrasbi 
& Sheikh, 2007, Muraro et al., 2007, as cited in Choo et al., 2010). Short term glucocorticoid 
treatment is seldom associated with adverse effects (Choo et al., 2010). 
Additionally short and rapid acting ǃ2-adrenergic agonist, salbutamol is recommended in 
nebulised form in doses of 2.5 mg/3 mL in children or 5 mg/3 mL in adults to treat 
bronchoconstriction with combination of oxygen supplementation (Simons et al., 2011). 
Tremor, tachycardia dizziness are potential side effects in usual doses, where as headache, 
hypokalemia, vasodilation can be seen in overdoses (Simons et al., 2011). Vasopressors such 
as dopamine can be used to correct hypotension despite other interventions.  
It should be pointed out that the time taken by draw up and administration of a second-line 
medication such as H1- antihistamines, corticosteroids, ǃ2-adrenergic agonists should not 
cause a delay in the administration of the first line treatment of epinephrine, 
supplementation of oxygen or intravenous fluid resuscitation (Simons et al., 2011). 
In refractory anaphylaxis methylene blue is used in a number of case reports. In 
anaphylactic shock endothelial nitric oxide synthase-derived NO appears to be the principal 
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vasodilator. Therefore methylene blue by inhibiting nitric oxide synthesis inhibition blocks 
nitric oxide (NO)-mediated vascular smooth muscle relaxation and seems to be effective in 
these cases (Lieberman et al., 2010). Tranexamic acid was used to treat anaphylactic episodes 
associated with disseminated intravascular coagulation (Lieberman et al., 2010). 
The management of anaphylaxis in pregnancy is similar to the management of non-
pregnant patients. The correct posture of the patient is also important. She has to be placed 
semi recumbent on her left side with the lower extremities elevated, to prevent positional 
hypotension resulting from compression of the inferior vena cava by gravid uterus (Simons 
et al., 2011).  
10. Prevention  
Long-term preventive measures to reduce the risk of fatality of anaphylaxis include 
avoidance of triggers, optimal management of relevant comorbidities such as asthma, 
cardiovascular diseases, mastocytosis and immunomodulation (Simons, 2009b).  
When anaphylaxis has occurred because of exposure to a specific trigger, patients should be 
educated about agents or exposures that would place them at risk for future reactions and 
be counseled on avoidance measures that may be used to reduce risk for such exposures 
(Lieberman et al., 2010). Triggers should be identified with a detailed history, and the 
sensitization to the triggers should be confirmed by using allergen skin tests and/or 
measurement of allergen-specific IgE levels in serum or challenge tests especially for 
therapeutic agents or foods. Optimally the patients can be tested for IgE sensitizations 
approximately 3-4 weeks after an acute anaphylactic episode. The time interval has not been 
definitely identified for most of the allergens, preferably patients with a convincing history 
of anaphylaxis and a negative test result should be retested afterwards. Challenge tests 
should be conducted in an appropriately equipped healthcare setting staffed by trained and 
experienced healthcare professionals as a supervised, graded test in order to diagnose and 
to assess risk of future anaphylactic episodes further. Before a challenge is performed the 
potential risk versus the potential benefit should be discussed with the patient and 
documented in the medical record (Simons et al., 2011).  
Absolute avoidance of triggers such as allergens like latex, foods, or a medication is life 
saving, but as an example lifelong avoidance of a food may disrupt daily life and may lead 
to anxiety or decrease the quality of life of the patients and their families or may lead to 
nutritional deficiencies, especially in children (Simons, 2009b). Additionally avoidance is 
difficult to perform in some situations. For example hidden, substituted, and cross-reacting 
foods, or foods that are contaminated and mislabeling or confusing labels on packaged 
foods are some of the reasons of difficulties in avoidance of triggers. So patients with food 
anaphylaxis should be informed about all of these possibilities, regularly provided 
personalized written instructions for avoidance of the confirmed specific triggers (Simons et 
al., 2011). Biphasic reactions appear to be more common in food-induced anaphylaxis when 
compared to other reasons of anaphylaxis and it is reported in up to 25% of fatal or near 
fatal reactions (Lieberman, 2005, as cited in Lieberman et al., 2010). Although it is rare for 
patients with oral allergy syndrome to develop anaphylaxis, they may be at increased risk. 
Therefore these patients may be prescribed epinephrine auto-injectors (Kleine-Tebbe et al., 
2002, as cited in Lieberman et al., 2010). Another important trigger to which avoidance is 
difficult is the stinging insects. Beekeepers, gardeners, others with occupational exposure 
may find it difficult to follow this advice (Lieberman et al., 2010; Simons et al., 2011). In 
www.intechopen.com
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
188 
patients with a history of anaphylaxis triggered by a medication should not be given the 
offending drug, and if available a safe, non-reacting alternative medication should be 
substituted. Patients should be informed about the offending drug, related and cross-
reactive drug with written documents (Simons et al., 2011). During anesthesia patients are 
under drapes and are unconscious, so early cutaneous signs are often unrecognized (Brock-
Utne, 2003). Therefore the staff has to be prepared and ready for unexpected anaphylaxis. 
Patients who experience anaphylaxis during the peri-operative period should be carefully 
evaluated to elucidate the responsible agent and be examined by an allergist prior future 
procedure. In the case of anaphylaxis due to radiocontrast agents, non-ionic radiocontrast 
agents should be considered as alternatives (Lieberman et al., 2010; Simons et al., 2011). 
In exercise-induced anaphylaxis avoidance of relevant co-triggers such as foods, 
medications, cold or hot air exposure, or other concomitant factors should be considered 
(Simons, 2009b). Exercise under ambient conditions of high humidity, extreme heat or cold 
or high pollen counts should be avoided (Simons et al., 2011). These patients should never 
exercise alone, should stop exercise immediately with the first symptom of anaphylaxis, and 
should carry a mobile phone and an epinephrine auto-injector during every exercise 
(Lieberman et al., 2010; Simons et al., 2011).  
In latex induced anaphylaxis avoidance of latex and if relevant, also the avoidance of cross-
reactive fruits, vegetables is extremely important (Lieberman et al., 2010; Simons et al., 
2011). Latex can enter the body through different routes including, mucous membranes, 
contact with the skin, parenteral exposure, and contact with internal organs as in surgery 
and with inhalation of latex powder. Therefore avoidance measures for latex allergy should 
be intensively applied to establish a latex-safe environment for the patients. Both latex-
sensitive healthcare workers and their co-workers should wear non-latex or non-powdered 
gloves and all non-glove latex devices should be replaced by non-latex devices. The most 
important procedures during which latex avoidance should be instituted in latex-sensitive 
patients include surgical procedures, obstetrical or gynecologic examinations or dental care 
(Lieberman et al., 2010). The problem can also manifest itself when latex sensitive patients 
experience anaphylaxis with related foods. These patients should be informed about the 
possible foods known to be cross-reactive latex. For anaphylaxis induced by some 
nonimmune triggers such as cold, heat, sunlight or ethanol, avoidance of the trigger is the 
key to prevention of recurrence (Simons et al., 2011). 
Anaphylaxis due to allergen specific immunotherapy is another important cause of 
anaphylaxis which can be strongly avoided when this treatment is administered by 
healthcare professionals trained in the recognition and treatment of anaphylaxis. In patients 
using ǃ-blockers the beneficial therapeutic effects of epinephrine may be diminished. 
Therefore a cautious attitude should be adopted in patients receiving concomitant ǃ-
blockers and allergen specific immunotherapy (Lieberman et al., 2010).  
Seminal fluid anaphylaxis is a rare condition, which can not be generally prevented with 
antihistamines or intravaginal cromolyn sodium taken as precoital medications, where as 
barrier condoms are successful options for prevention. When these therapies are not 
effective or unacceptable, immunotherapy with seminal plasma fractions can be instituted in 
specialized centers (Lieberman et al., 2010). 
The accompanying medications which can interfere with anaphylaxis and management such 
as ǃ-blockers, angiotensin-converting enzyme inhibitors, NSAIDs, aspirin should be given 
weighing the risks and benefits of each medication (Lee & Vadas, 2011).  
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Oral desensitization to a specific food, subcutaneous anti-IgE injections, Food Allergy 
Herbal Formula-2, a well-characterized Chinese herbal formulation are investigational 
immunomodulator interventions being studied in humans for the prevention of anaphylaxis 
(Simons, 2009b). Desensitization strategies with the offending drug, where an alternative 
drug is not available are safe and effective immunomodulatory approaches particularly in 
patients with anaphylaxis due to ǃ-lactam or other antibiotics, aspirin, or other nonsteroidal 
anti-inflammatory drugs, and chemotherapy agents. This procedure should be conducted by 
trained and experienced healthcare professionals in healthcare settings where all facilities 
for the management of anaphylaxis are available. This method provides protection only 
during the procedure as a temporary state of tolerance (Simons et al., 2011). Where as long-
lasting protection against anaphylaxis can only be achieved with successful allergen specific 
immunotherapy which is mostly seen in subcutaneous venom immunotherapy (Simons, 
2009b). It protects up to 80-90% of adults and 98% of children, in whom it lasts for decades 
(Simons et al., 2011). Latex sublingual immunotherapy has been shown to be an effective 
treatment in double blind placebo controlled studies both in children and adults, but 
according to our experience in the dose incremental phase precautions should be taken 
(Bernardini et al., 2008; Buyukozturk et al. , 2010). 
In patients with frequent recurrent episodes of idiopathic anaphylaxis, empiric use of 
prednisone in a daily dose of 60-100 mg in combination with H1-antihistamines for 1-2 
weeks followed by decreasing alternate day prednisone over 3 months as prophylaxis is 
recommended by the experts and has been demonstrated to reduce the frequency or 
severity of episodes (Lieberman et al., 2010). This treatment is considered in patients 
experiencing 6 or more episodes per year or 2 episodes in 2 months (Lieberman et al., 2010). 
Anti-IgE treatment is also promising (Simons, 2009b; Simons et al., 2011). These patients 
should carry their epinephrine auto-injectors at all times. Pretreatment strategies with 
antihistamines and corticosteroids have been used successfully to prevent anaphylaxis due 
to radiocontrast agents, cold-induced anaphylaxis and fluorescein (Lee & Vadas, 2011; 
Simons, et al., 2011). 
Despite these preventive measures anaphylaxis sometimes recurs. Therefore, those at risk, 
should be prepared to recognize and treat unexpected episodes and be educated. 
Anaphylaxis education should begin before patients are discharged from the emergency 
department or other healthcare facility where the anaphylaxis was treated (Simons et al., 
2011). Patients should be informed about the importance of the reactions that they have 
experienced. For this purpose, patients should carry medical identification prepared as a 
bracelet or a wallet card listing their diagnosis of anaphylaxis, confirmed trigger factors, 
relevant comorbidities, and concurrent medications (Simons, 2009b; Simons et al., 2011). 
They should be also advised that they are at increased risk for future episodes of 
anaphylaxis and therefore need follow-up, preferably by an allergy/immunology specialist 
(Simons et al., 2011) and prescribed for epinephrine auto-injectors and have their 
personalized written anaphylaxis emergency action plans (Simons 2009b; Liebermann et al., 
2010). If epinephrine auto-injectors are not available or affordable, a substitute epinephrine 
formulation should be recommended, such as an ampoule of epinephrine, a 1 ml syringe, 
and written instructions about drawing up the correct dose. In emergency action plans, 
patients should be briefly informed about how to recognize anaphylaxis symptoms, 
instructed to inject epinephrine promptly and then admit to emergency to seek medical 
assistance (Simons et al., 2011).  
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Delayed injection or non-injection of epinephrine has been shown to be a risk factor for 
severe and biphasic reactions and fatal outcome (Gallagher et al., 2011; Lee & Vadas, 2011; 
Simons et al., 2010). Therefore patients are commonly prescribed at least two auto-injector 
devices for the administration of epinephrine in the community settings for this sudden, 
rapid, and usually unexpected clinical situation (Gallagher et al., 2011; Kemp et al., 2007). 
There is clear consensus in the research literature that these auto-injectors are under-used by 
patients of all-ages (Gallagher et al., 2011; Simons, 2009b, Simons et al., 2011). A recent paper 
suggested that auto-injector under-use is commonly due to patients preferring to take other 
medications most commonly antihistamines, not having auto-injector prescriptions, lack of 
severity of previous episodes or spontaneous recovery from previous episodes (Simons et 
al., 2009a). A recent study demonstrated that in addition to demonstrating injection 
technique, several other points must also be elucidated to the patients (Gallagher et al., 
2011). They should be informed that auto-injectors should be used swiftly rather than 
waiting. They should be trained in recognizing anaphylaxis, taking into account the wide 
variability of symptoms and the side effects of epinephrine, offering reassurance about its 
safety if used unnecessarily (Gallagher et al., 2011). It should also be pointed out that an 
anaphylactic episode doesn’t possess a predictive value for the severity of future episodes 
because of variable target organ involvement and the influence of comorbid illness and 
concurrently medications (Simons et al., 2009a).  
The currently available epinephrine auto-injectors have some structural limitations (Frew, 
2010). There are two types of delivery systems either as cartridge-based or a syringe delivery 
system used in the currently available auto-injectors (Frew, 2010). Evidence suggests there 
are several clear advantages of auto-injectors that utilize a cartridge system compared with a 
syringe system, but they are found in only 2 fixed doses as 0.15 mg which may be too high 
for infants and young children weighing less than 15 kg and 0.3 mg which can be a low dose 
for some children and adults, especially those who are overweight or obese (Frew, 2010; 
Simons, 2009b). Additionally the needle is 1.43 cm, not allowing optimal intramuscular 
injection in especially obese patients. New compact, lightweight, auto-injectors providing a 
0.5 mg dose per injection, with a needle length of 2.54 cm are being designed and 
noninjectable epinephrine preparations for sublingual or transdermal administrations are 
also in development (Frew, 2010; Simons, 2009b). 
The reasons for lack of response to epinephrine can be summarized as the error in the 
diagnosis, the wrong position of the patient after the injection, the rapid progression of 
anaphylaxis, the presence of a beta-adrenergic blocker or interfering drugs in the patient’s 
medications, the low dose or the delayed injection of epinephrine, and the suboptimal route 
or injection site (Simons et al., 2011). Therefore the aim of every physician should be to teach 
their patients when and how to inject epinephrine and to educate them about anaphylaxis 
and save their lives. 
11. Conclusion  
Anaphylaxis is a serious acute allergic reaction and has to be recognized with signs and 
symptoms involving various organ systems and treated promptly. To diminish the risk for 
further attacks detailed history has to be taken carefully from the patients including the 
potential triggers or events, the clinical signs and symptoms. Laboratory tests most 
importantly an elevated serum tryptase level sometimes but not always support the 
diagnosis. The trigger has to be removed, if possible and the patient’s circulation, airway, 
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breathing, level of consciousness, and skin should be rapidly assessed. Epinephrine is the 
cornerstone of the treatment. Patients should be kept in the correct position, oxygen and 
fluid supplementation should be given. Antihistamines, corticosteroids, and other agents 
are the second-line treatment agents. Patients should be informed about the potential risk 
for the future attacks and be educated and prepared. For this purpose, patients should carry 
medical identification and be prescribed for epinephrine auto-injectors and have their 
personalized written anaphylaxis emergency action plans. 
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